NCT00140738View on ClinicalTrials.gov

Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

March 10, 2005

Primary Completion Date

September 29, 2008

Study Completion Date

September 29, 2009

Conditions
Neoplasms, Breast
Interventions
BIOLOGICAL

GSK Biologicals' 719125

Patients receive six vaccinations at two-week intervals

Trial Locations (14)

1340

GSK Investigational Site, Ottignies

3500

GSK Investigational Site, Hasselt

6000

GSK Investigational Site, Charleroi

20141

GSK Investigational Site, Milan

31052

GSK Investigational Site, Toulouse

34298

GSK Investigational Site, Montpellier

44805

GSK Investigational Site, Saint-Herblain

54511

GSK Investigational Site, Vandœuvre-lès-Nancy

69373

GSK Investigational Site, Lyon

75248

GSK Investigational Site, Paris

92210

GSK Investigational Site, Saint-Cloud

11001000

GSK Investigational Site, Bogotá

00133

GSK Investigational Site, Rome

Lima 34

GSK Investigational Site, Lima

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00140738 - Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter